Precision Medicine in the Prostate Cancer Care Pathway

Institute of Cancer Research, United Kingdom3,000 enrolled

Overview

This study aims to evaluate the use of a prostate cancer specific predisposition genetic panel test in men with / at high risk of prostate cancer. The genetic test will analyse men's DNA samples for the presence of mutations in rare genes as well as common genetic variation to provide men with information about their risk of prostate cancer. This study will evaluate the clinical impact of the test on risk assessment and clinical management in terms of screening and treatment.

Study Type

OBSERVATIONAL

Enrollment

3,000

Conditions

Prostate Cancer Genetic Predisposition

Interventions

Prostate cancer risk gene panelGENETIC

A list of genes created by study experts, thought to increase the risk of prostate cancer from from review previous research, this list is regularly reviewed for accuracy

Medical Language ↔ Plain English

Inclusion Criteria: Affected cohort: 1. Affected with PrCa \< 60 years or 2. Affected with metastatic castration resistant PrCa (mCRPC) at any age or Aggressive PrCa Gleason 4+4 or higher \<70 years 3. Affected with family history defined as three or more cases any age (FDR or SDR) Unaffected cohort: (This cohort is no longer recruiting, it has completed recruitment) Aged \>30 and with a family history defined as: 1. FDR diagnosed \< 70 2. 2 or more cases in First or Second Degree Relatives (FDR/SDR) with one case diagnosed \< 70 years 3. 3 or more cases at any age (on same side of family) Exclusion Criteria: * • WHO performance status 4

Outcomes

Primary Outcomes

Prevalence of genetic variation in affected men

To determine the prevalence of prostate cancer (PrCa) specific genetic variation in men with: (a)young onset PrCa; (b) metastatic PrCa; (c) men with PrCa and a family history of PrCa compared with controls.

Time frame: Through study completion, an average of 1 year

Secondary Outcomes

Prevalence of genetic variation in unaffected men

To determine the prevalence of prostate cancer specific genetic variation in unaffected men with a strong family history of prostate cancer compared with controls.

Time frame: Through study completion, an average of 1 year

Prostate Cancer genetic variation on clinical outcome

To determine how prostate cancer specific genetic variation influences clinical outcome in 'high-risk' vs 'low risk' groups.

Time frame: Through study completion, an average of 1 year

Precision Medicine in the Prostate Cancer Care Pathway

Overview

Conditions

Interventions

Eligibility

Locations (1)

Outcomes

Primary Outcomes

Secondary Outcomes